1 ϫ 10 1 ϫ 10 1:1 randomization with placebo recipients. Infants received the vaccine at 8, 12, and 16 weeks, separately from routine vaccines.
Results. No significan differences in clinical adverse events or laboratory toxicity were observed between vaccine and placebo recipients. There were no vaccine-related serious adverse events. A 4-fold increase in rotavirus immunoglobulin A titer was observed in 66.7% and 64.5% of infants after the firs administration and in 62.1% and 89.7% of infants after 3 administrations of doses of ffu and ffu, respectively; the differences 4 5 1 ϫ 10 1 ϫ 10 between these groups and placebo recipients were statistically signific nt.
Conclusions. Three administrations of vaccine doses of ffu and ffu were safe. The -ffu 4 5 5 1 ϫ 10 1 ϫ 10 1 ϫ 10 dose of 116E demonstrated a robust immune response after 3 administrations. These favorable results warrant further development of the vaccine candidate and provide optimism that vaccinating infants in the developing world will prevent serious sequelae of rotavirus infection.
Clinical trials registration. NCT00439660 and ISRCTN57452882.
Rotavirus infections are estimated to cause ∼527,000 deaths annually, predominantly in developing countries [1] . In India, 1 of 250 children per year will die from rotavirus diarrhea [2] , and ∼122,270 rotavirus-attributable deaths per year occur among children aged !5 years [1, 3] . The development and introduction of a rotavirus vaccine has been accorded high priority globally [1, 4, 5] . In India, 70%-80% of cases of rotavirus diarrhea occur in the firs year of life, and a relatively high percentage of infections involve multiple serotypes and unusual strains. Severe disease usually spares infants in the firs few months of life, perhaps because of the high titers of transplacental antibodies [6] .
Two rotavirus vaccines have been developed and tested exclusively for safety in Europe, Latin America, and the United States and have been licensed in 1100 countries [7, 8] . However, the efficac of these vaccines in low-income countries in Asia has not yet been demonstrated, and the current price structure would make these vaccines unaffordable in the Indian National Program for Childhood Immunization. In the national program, most vaccines are supplied by domestic manufacturers to ensure affordability and sustained access [9] . As a part of the Indo-US Vaccine Action Program and with technical support from the Department of Biotechnology (India), the US Centers for Disease Control and Prevention (CDC), the National Institutes of Health, Stanford University, and PATH, the oral rotavirus vaccine (ORV) 116E is in development by Bharat Biotech International Limited (Hyderabad, India) to address the need for a safe, effective, and affordable vaccine for India and the developing world [10] .
Several studies have documented that the firs rotavirus infection in infants protects against severe diarrhea during reinfection [11, 12] . In the mid-1980s, neonates born at the All India Institute of Medical Sciences (New Delhi) were commonly infected with a rotavirus strain before hospital discharge that was later encoded 116E. These infants remained asymptomatic and experienced 46% fewer episodes of rotavirus diarrhea than did a cohort of babies born at All India Institute of Medical Sciences who were not neonatally infected [13] . Because infection with strain 116E did not cause diarrhea in newborns and was not found in older patients with diarrhea, it appeared to be naturally attenuated. Furthermore, the strain grew well in the infant gut, induced rotavirus-specif c immunoglobulin (Ig) A or IgM antibody responses, and offered clinical protection [13, 14] . Because rotaviruses do not commonly infect infants in the firs few months of life, this strain was unique in that it grew in the presence of transplacental antibodies from the mother.
Strain 116E was characterized as a human rotavirus of serotype G9,P [11] with a single gene encoding VP4, the outer capsid protease-cleaved pike hemaglutinin that was naturally reassorted from a bovine rotavirus strain [15, 16] . It was developed as a vaccine candidate after passaging in primary AGMK, MA104, and SPAGMK cells by Dyncorp-PRI, under contract with the National Institutes of Health. The passage history has been described elsewhere [10] . A single administration of this candidate vaccine was evaluated in 30 adults and 30 children in the United States and India and in 90 infants in India at a dose of focus-forming units (ffu) and was 5 1 ϫ 10 found to be safe and immunogenic [10, 17] .
The strain was adapted to grow on Vero cells by Bharat Biotech International Limited and was formulated as the candidate vaccine. We report the results of a phase I/II safety and immunogenicity trial involving healthy infants aged 8-20 weeks who received the Vero cell-based 116E neonatal rotavirus vaccine candidate strain at a low dose (define as ffu) and 4 1 ϫ 10 a high dose (define as ffu). The vaccines were ad- 5 1 ϫ 10 ministered to infants as 3 administrations separately from routine childhood vaccines. Blood samples were obtained from subsets of 30 infants after each administration to measure the immune response to the vaccine and to assess the vaccine dose and number of administrations to be considered for an effi acy trial.
PATIENTS, MATERIALS, AND METHODS
Study population. The trial was conducted from November 2006 through February 2008. Infants were identif ed through a survey conducted in urban middle to low class neighborhoods in New Delhi. Consent was obtained at the study clinic when infants were aged 6 weeks (up to an additional 2 days). Infants were excluded if their families did not have access to a telephone, they would not be available for follow-up, and they had a weightfor-height z score of р3 standard deviations [18 ], they resided with an immunocompromised individual, they were born at a gestational age of !37 weeks, they had major congenital abnormality, or they had a history of hospitalization for sepsis, pneumonia, or meningitis. Other exclusion criteria were diarrhea in the previous 7 days, blood in stools any time after birth, or the need for daily medication. Infants with cardiovascular or neurological disease; lymphadenopathy; hepatosplenomegaly; abnormal laboratory markers, such as serum bilirubin level, serum glutamate oxaloacetate transaminase level, serum glutamate pyruvate transaminase level, alkaline phosphatase level, hemoglobin level, platelet count, total leukocyte count, serum creatinine level, presence of hepatitis B surface antibody, detection of anti-hepatitis C virus antibody, urine albumin level, or hematuria, were also excluded [19, 20] .
Infants received 3 doses of vaccines against diphtheria, pertussis, and tetanus; oral polio (OPV); and hepatitis B virus at 6, 10, and 14 weeks of age. ORV 116E or placebo was administered at 8, 12, and 16 weeks of age. After discussion with community leaders and families, parents agreed to participate if only 2 blood samples per child were obtained. Consequently, to determine the number of doses required, we enlarged the study so that groups of 30 infants could have blood samples obtained before and after the first second, and third administration. The study was approved by the Ethical Review Committees of the Society for Applied Studies, Department of Biotechnology, PATH Human Subjects Protection Committee, Stanford University, and the CDC, as well as by the Drugs Controller General of India. The International Conference on Harmonisation/World Health Organization (WHO) Good Clinical Practice guidelines, ethical principles of the Declaration of Helsinki, and the Indian Council of Medical Research were followed [21, 22, 23] .
Randomization. Infants were assigned to either the vaccine or placebo groups in a 1:1 ratio with use of a randomization sequence generated by a statistician not otherwise involved with the study (Stata software, version 8.0) with a fixe block length of 4. One-third of the infants in each group were allocated to have blood samples obtained at 1 of the 3 ages (12, 16, or 20 weeks). Allocation concealment was achieved by using serially numbered sealed opaque envelopes. One set of envelopes was available with the independent vaccine dispensing team and another with the study data safety monitoring board.
Vaccine and its administration. The rotavirus strain 116E was isolated, and tissue culture was adapted by 2 passages in primary AGMK cells at the CDC (Atlanta, GA). After 2 plaque purification in MA104 cells, the clone was stored frozen. After thawing, the clone was serially passaged twice in MA104 cells, and an aliquot of the fina harvest was submitted to DynCorp-PRI for scale-up and experimental live virus vaccine production in SPAGMK cells [17] .
Vero cells were selected as the substrate for adaptation and eventual production of the vaccine, because this cell line had previously been approved for vaccine production by the National Regulatory Authority of India [23] . The master cell bank and manufacturer's working cell bank were produced by seed lot system in accordance with guidelines of the Indian Pharmacopoeia 1996 and the WHO [24] . The development and production of ORV 116E was based on standard operating procedures, standard testing procedures, manufacturing formula, and batch records, as required by the National Regulatory Authorities (schedule Y), International Conference on Harmonisation guidelines, and WHO requirements and guidelines for the production and control of vaccines based on cell substrates [25] [26] [27] [28] . Master and working cell banks of Vero cells were tested and characterized by BioReliance (Rockville, MD). Preclinical toxicity testing was performed by Covance Research Products (Denver, PA).
Each 0.5 mL of the vaccine contained ffu of ro-
1 ϫ 10 tavirus 116E for the -ffu dose and ffu of 4 5 ‫5.0ע‬
1 ϫ 10 1 ϫ 10 rotavirus 116E for the -ffu dose, in addition to stabilizers 5 1 ϫ 10 and excipients. Each 0.5 mL of placebo contained the same constituents, except the virus. Vaccine and placebo were stored at Ϫ ЊC and were similar in appearance and taste. A 2.5-70 ‫ע‬ 5 mL dose of the sterile citrate bicarbonate buffer was available in a vial and was stored at 2ЊC-8ЊC; it was administered at least 5 min before the test article. Parents were requested not to feed infants for 30 min before and after administration of the test article.
Safety evaluation. Unexpected and expected adverse events were monitored during the 2-week period after each administration of the test article. Monitoring for intussusception was done throughout the follow-up period. Any infant who had blood in their stool, continuous vomiting, inconsolable crying, abdominal distension, or an abdominal lump was taken to a hospital. Changes in selected laboratory indicators of toxicity (i.e., serum creatinine, serum glutamate oxaloacetate transaminase, serum glutamate pyruvate transaminase, hemoglobin, serum bilirubin, and alkaline phosphatase levels; total leukocyte count; platelet count; and proteins and RBCs in urine) [19] were tested 4 weeks after the firs administration of each dose in one-third of the infants in an ISO 15189 laboratory accredited by the Government of India [29] . Infants were visited at home for 14 days after each administration of the test article to measure their temperature and document illness in the previous 24 h. Parents were asked to call study physicians with use of a 24-h hotline. Physicians examined and treated all ill infants.
Before administration of the test article, physicians assessed infants for contraindications, such as diarrhea, fast breathing, temperature 139.5ЊC, convulsions, lethargy, unconsciousness, inability to drink or breastfeed, vomiting, passage of blood in stools in the previous 48 h, and laboratory toxicity (grade, 12) [19, 20] .
A data safety monitoring board was constituted with a pharmacologist, a statistician, and 2 pediatricians (who were also the independent safety monitors for the study). After completion of the 12-week safety follow-up period for all infants in the low-dose cohort, the data safety monitoring board reviewed the study finding and approved evaluation of the -ffu 5 1 ϫ 10 dose.
Adverse event reporting. Adverse events were graded for severity and relatedness to the test article by the investigators. Events that were severity grade 3 or higher (i.e., events that interrupted the infant's usual daily activities and required systemic or other treatment) and serious adverse events were reviewed by an independent safety monitor. Severe adverse events (define as medical events that resulted in hospitalization or death) were reported to ethics committees, the sponsor, and the regulatory authorities within 72 h after identific tion.
Viral shedding and immunogenicity. Stool specimens were collected before administration of the test article (day 0) and on days 3 (window, days 2-6), 7 (window, days 7-14), and 28 (window, days 26-30) after administration of the test article during episodes of diarrhea and when any signs or symptoms of suspected intussusception were present to ascertain shedding of the vaccine virus. Rotavirus was detected in stool samples with use of a commercial enzyme immunoassay (Premier Rotaclone; Meridian Bioscience), according to manufacturer's guidelines. All stool samples that tested positive with the Rotaclone were analyzed for G (VP7) and P (VP4) genotype by multiplex polymerase chain reaction (PCR) with use of methods described elsewhere [30, 31] .
Blood samples (1.5 mL) were collected from all infants before firs administration of the test article and from one-third (30 vaccine recipients and 30 placebo recipients) of infants 28 days after the first second, and third administration. Seroconversion rates were determined by analysis of paired serum samples (from before and after vaccination) for anti-rotavirus IgA titers.
Serum rotavirus-specifi IgA antibody titers were estimated using an enzyme linked immunosorbent assay (ELISA) for the 2 blood specimens collected from each enrolled infant. Seroconversion was define as a 4-fold increase in IgA antibody titer to rotavirus in paired serum samples obtained before and after test article administration. Levels of rotavirus-specifi serum IgA were determined using an ELISA with a standard curve method [32] . Serum samples were screened at a dilution of 1:20 or 1:200. The sensitivity of the assay or the lower detection limit was 4 U/mL. If rotavirus IgA was not detectable in a sample, the concentration used for estimating the vaccine take (i.e., to determine 4-fold increases in titer) was 2 U/mL, which corresponded to 50% of the lower detection limit of the ELISA.
Data management and analyses. Databases were created in Visual Basic (Microsoft), and range and consistency checks were built in. Double data entry was done within 72 h. Data file were validated, and corrections were made through data clarificatio forms. Data were analyzed using Stata software (version 8.2; Stata).
Clinical symptoms and laboratory toxicities are presented as proportions. Seroconversion rates are presented as proportions with 95% confidenc intervals of the differences in the proportions between the vaccine and placebo groups. Fischer's exact test and the x 2 test were used to test statistical signifi ance between proportions.
RESULTS
Of the 778 infants identifie for screening at 6 weeks of age, 187 (24%) were enrolled at 8 weeks of age in the -ffu 4 1 ϫ 10 dose trial. The common reasons for exclusion are summarized in figu e 1. The mean age ‫ע(‬ standard deviation [SD]) at enrollment was days in the ORV 116E group and 56.8 ‫ע‬ 1.2 days in the placebo group (table 1) . Ninety-three 57.1 ‫ע‬ 1.4 infants were randomized to the ORV 116E group, and 94 were randomized to the placebo group.
A total of 789 infants were screened for the -ffu dose 5 1 ϫ 10 trial, and 182 (23%) were enrolled. The reasons for exclusion are given in figu e 1. The mean age (‫ע‬SD) at enrollment was days in the vaccine group and days in the 57.0 ‫ע‬ 1.5 57.0 ‫ע‬ 1.6 placebo group (table 1) . Ninety-two infants were randomized to the ORV 116E group, and 90 were randomized to the placebo group.
Adverse events and serious adverse events. There were no significan differences between the vaccine group and the placebo group in the proportion of infants who had expected adverse events that were adjudged to be probably, possibly, or remotely related to the test article (table 2). Infants in this community normally have a high prevalence of diarrhea, and this was observed in our cohorts. Overall, with the -ffu 4 1 ϫ 10 dose given during the 0-14-day window after administration, 19 infants in the vaccine group and 23 in the placebo group had diarrhea with or without vomiting after the fi st administration, compared with 25 and 15, respectively, after the second administration and 26 and 34, respectively, after the third administration (
). With the -ffu dose, the num-5 P 1 .05 1 ϫ 10 bers of infants who had diarrhea with or without vomiting during the 0-14-day window after the first second, and third administration of the test article were 17 in the vaccine group and 18 in the placebo group; 16 and 12, respectively; and 14 and 6, respectively ( ). The proportions of infants with P 1 .05 vomiting after each of the 3 administrations of both doses were similar (table 2) . Infants with a history of fever or a measured temperature 137.5ЊC were also similar in the vaccine and placebo groups after each of the 3 administrations of the -ffu and -ffu doses. Other adverse events, such 4 5 1 ϫ 10 1 ϫ 10 as cough or runny nose, irritability, and rash, were common with both doses, but none of these events were judged to be related to the vaccine.
Seven severe adverse events were reported with the - 4 1 ϫ 10 ffu dose, and 8 were reported with the higher dosage; none of these events were assessed to be vaccine related. No clinically significan differences were observed in the hematological or 1 ϫ 10 group, compared with 13.3% in the placebo group, had a у4-fold increase in IgA titers from baseline after the fi st administration; 62.9%, compared with 22.6%, had this increase after the second administration; and 62.1%, compared with 22.6%, had this increase after the third administration. With the -ffu dose, these rates were 64.5% in the vaccine group, 5 1 ϫ 10 compared with 23.3% in the placebo group, after the fi st administration; 67.7%, compared with 21.4%, after the second administration; and 89.7%, compared with 28.1%, after the third administration (table 4) .
DISCUSSION
This trial demonstrated seroconversion in 90% of infants who received 3 administrations of the high-dose vaccine in the target population. Furthermore, 160% responded to a single dose of either the high-or low-titer formulations. These rates are comparable to those reported for the Rotashield vaccine (Wyeth Laboratories) tested in Bangladesh (87%) [34] ; however, they are significantl higher than those reported for the monovalent human rotavirus vaccine Rotarix (GlaxoSmithKline) in Ban-gladesh (55% with OPV and 65% without OPV) [35] . The rate of seroconversion after 1 low dose of the neonatal strain was comparable to that after 2 doses of Rotashield. The trial with Rotarix has been performed in India, but no data have yet been reported [36] . Administration of both the low and high doses of ORV strain 116E was safe in infants aged 8-20 weeks. The prevalence of expected adverse events was low in both groups, and there was no evidence of any changes in the laboratory markers. The vaccine was immunogenic with a single dose and reached immunogenic rates of 89.7% with 3 doses of the -ffu 5 1 ϫ 10 formulation. The vaccine virus was shed in ∼20% of infants, and shedding was almost always accompanied by an immune response.
Although seroconversion is not a direct proxy for effi acy, it does demonstrate that the virus is able to colonize the infant gut and induce a robust immune response [37, 38] . Only an efficac trial will provide the definitiv evidence required. Of note, Rotarix is routinely administered as a 2-dose regimen [39] ; however, because the immune response in South African and Bangladeshi infants was relatively modest, a 3-dose regimen was also evaluated in the recent efficac trial in South Africa [40] . Our finding and the original identificatio of this strain from neonates suggest the possibility that the presence of the VP4 gene from a bovine strain in 116E might permit replication of the vaccine in the presence of high titers of maternal antibody and that a neonatal strain-based vaccine might perform better in neonates [41] .
The rate of shedding of the vaccine in stool during the trial was low, compared with that of Rotarix, but greater than that of Rotateq (Merck) [42, 43] . The single child in the placebo group who shed a G9,P [11] rotavirus strain could have been infected naturally at the place of birth or thereafter.
Our study has some limitations. Safety of ffu of 116E 5 1 ϫ 10 grown in AGMK cells was assessed in only 90 infants and in 30 infants previously [17] . Severe but uncommon adverse effects, such as intussusception, would only become evident during larger trials or during postmarketing surveillance; the WHO recommends that postmarketing surveillance for rare adverse events, including intussusception, be used to evaluate this risk [44] . Second, the vaccine was administered separately from the other childhood vaccines, including OPV. Data demonstrating the lack of interference between ORV 116E and the immune responses to other childhood vaccines will be critical if 116E is to be used effectively as part of the routine program of childhood immunization; a trial to examine possible interference will begin shortly. We obtained only 2 serum specimens per infant; thus, our serology data were drawn from different subgroups of ∼30 infants each after each of the 3 administrations. A possible confounder in this approach was the potential high background rates of natural infection among these infants, which is typical in southern Asia [34] . The seroconversions in the placebo group, however, were not associated with acute gastrointestinal symptoms but were associated with asymptomatic infections; thus, infants who experienced seroconversion could be immune from natural exposure. At this early stage of evaluation of this vaccine, the exclusion criteria used were stringent, and the number of exclusions was unexpectedly high; most exclusions occurred because of laboratory values outside the predefine range (serum bilirubin level, serum glutamate pyruvate transaminase level, total leukocyte count, and alkaline phosphatase level). We can only speculate that these laboratory marker abnormalities may be unique to infants in this setting, where impairment during intrauterine growth and in micronutrient status is common.
The high level of immunogenicity suggests that 116E may be a particularly useful vaccine in developing countries, where high titers of transplacental rotavirus antibodies may inhibit the immune response to live oral vaccines. These encouraging results justify conducting a large clinical trial to evaluate the protective efficac of the 116E vaccine in a fiel setting. Further evaluation of this vaccine must use less stringent enrollment criteria to yield more-generalizable f ndings.
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